Deutsche Märkte geschlossen

Jazz Pharmaceuticals plc (JAZZ)

NasdaqGS - NasdaqGS Echtzeitpreis. Währung in USD
Zur Watchlist hinzufügen
140,46+3,24 (+2,36%)
Ab 3:56PM EDT. Markt geöffnet.

Jazz Pharmaceuticals plc

Waterloo Exchange
Fifth Floor Waterloo Road
Dublin 4
Ireland
353 1 634 7800
http://www.jazzpharma.com

Sektor(en)Healthcare
BrancheBiotechnology
Vollzeitmitarbeiter1.940

Leitende Angestellte

NameTitelZahlenAusgeübtGeburtsjahr
Mr. Bruce C. CozaddCo-Founder, Chairman & CEO2,48M823,12k1964
Mr. Daniel N. Swisher Jr.Pres1,37MN/A1963
Ms. Renee D. GalaExec. VP & CFO924,52kN/A1972
Dr. Robert Iannone M.D.Exec. VP of R&D and Chief Medical Officer1,05MN/A1967
Ms. Kim SablichExec. VP & GM of North America869,48kN/A1969
Mr. Christopher John ToveyExec. VP, COO and MD of Europe & InternationalN/AN/A1965
Ms. Patricia CarrVP of Fin. & Principal Accounting OfficerN/AN/A1971
Dr. Finbar Larkin Ph.D.Sr. VP of Technical OperationsN/AN/A1958
Ms. Andrea N. FlynnVP & Head of Investor RelationsN/AN/AN/A
Ms. Neena M. Patil J.D.Chief Legal Officer and Sr. VP of Legal & Corp. AffairsN/AN/A1975
Die Beträge haben den Stand 31. Dezember 2020 und Kompensationswerte gelten für das letzte Geschäftsjahr bis zu diesem Datum. Der Lohn umfasst Gehalt, Boni usw. „Ausgeübt“ entspricht dem Wert von Optionen, die im Lauf des Geschäftsjahrs ausgeübt werden. Währung in USD.

Beschreibung

Jazz Pharmaceuticals plc, a biopharmaceutical company, identifies, develops and commercializes pharmaceutical products for various unmet medical needs in the United States, Europe, and internationally. The company has a portfolio of products and product candidates with a focus in the areas of neuroscience, including sleep medicine and movement disorders; and in oncology, including hematologic and solid tumors. Its lead marketed products include Xyrem, an oral solution for the treatment of cataplexy and excessive daytime sleepiness (EDS) in narcolepsy patients seven years of age and older; Sunosi for the treatment of EDS in patients with narcolepsy and obstructive sleep apnea; Erwinaze to treat acute lymphoblastic leukemia; Defitelio for the treatment of adult and pediatric patients with hepatic veno-occlusive disease; Vyxeos liposome for injection, a product for the treatment of adults with newly-diagnosed therapy-related acute myeloid leukemia; and Zepzelca for the treatment of adult patients with metastatic small cell lung cancer. The company also offers Xywav, an oxybate product candidate, to treat EDS and cataplexy with narcolepsy and idiopathic hypersomnia; JZP-324, a low sodium oxybate formulation with the potential to provide a clinically meaningful option for narcolepsy patients; JZP-385, a T-type calcium channel modulator, for the treatment of essential tremor; JZP-458, a recombinant Erwinia asparaginase, for use as a component of a multi-agent chemotherapeutic regimen in the treatment of pediatric and adult patients; and JZP-150 for treatment of post-traumatic stress disorder. Jazz Pharmaceuticals plc has licensing and collaboration agreements with ImmunoGen, Inc.; Codiak BioSciences, Inc.; Pfenex, Inc.; XL-protein GmbH; and Redx Pharma plc . The company was founded in 2003 and is headquartered in Dublin, Ireland.

Corporate Governance

Jazz Pharmaceuticals plcs ISS Governance QualityScore, Stand 26. September 2021, lautet 4. Die grundlegenden Scores sind Audit: 4, Vorstand: 3, Shareholderrechte: 4, Kompensation: 8.

Corporate-Governance-Bewertungen von Institutional Shareholder Services (ISS). Die Werte geben den Zehntelwert im Verhältnis zum Index oder zur Region an. Ein Zehntelwert von 1 zeigt geringeres Governance-Risiko, 10 höheres Governance-Risiko.